Balloon pulmonary angioplasty in chronic thromboembolic pulmonary hypertension: a multicentre registry.
Journal
EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology
ISSN: 1969-6213
Titre abrégé: EuroIntervention
Pays: France
ID NLM: 101251040
Informations de publication
Date de publication:
28 Jan 2022
28 Jan 2022
Historique:
pubmed:
6
7
2021
medline:
2
2
2022
entrez:
5
7
2021
Statut:
ppublish
Résumé
Balloon pulmonary angioplasty (BPA) is a promising therapy for patients with chronic thromboembolic pulmonary hypertension (CTEPH) who are ineligible for pulmonary endarterectomy. The present study aimed to evaluate the safety and efficacy of BPA for CTEPH using the first multicentre registry of a single European country. Data were obtained from the Database of Pulmonary Hypertension in the Polish Population (NCT03959748), a prospective, multicentre registry of adult and paediatric pulmonary arterial hypertension (PAH) and CTEPH, for a total of 236 patients with confirmed CTEPH (124 women; mean age 67 years) who underwent 1,056 BPA procedures at eight institutions in Poland. In 156 patients who underwent follow-up assessments after a median of 5.9 (IQR: 3.0-8.0) months after final BPA, the mean pulmonary arterial pressure decreased from 45.1±10.7 to 30.2±10.2 mmHg (p<0.001) and pulmonary vascular resistance from 642±341 to 324±183 dynes (p<0.001), and the six-minute walking test (6MWT) improved from 341±129 to 423±136 m (p<0.001). Pulmonary injury related to the BPA procedure occurred in 6.4% of all sessions. Eighteen patients (7.6%) died during follow-up, including 4 (1.7%) who died within 30 days after BPA. Overall survival was 92.4% (95% confidence interval [CI]: 87.6%-94.9%) three years after the initial BPA procedure. This multicentre registry confirmed significant improvement of haemodynamic, functional, and biochemical parameters after BPA. Complication rates were low and overall survival comparable to the results of another registry. Therefore, BPA may be an important therapeutic option in patients with CTEPH in Poland.
Sections du résumé
BACKGROUND
BACKGROUND
Balloon pulmonary angioplasty (BPA) is a promising therapy for patients with chronic thromboembolic pulmonary hypertension (CTEPH) who are ineligible for pulmonary endarterectomy.
AIMS
OBJECTIVE
The present study aimed to evaluate the safety and efficacy of BPA for CTEPH using the first multicentre registry of a single European country.
METHODS
METHODS
Data were obtained from the Database of Pulmonary Hypertension in the Polish Population (NCT03959748), a prospective, multicentre registry of adult and paediatric pulmonary arterial hypertension (PAH) and CTEPH, for a total of 236 patients with confirmed CTEPH (124 women; mean age 67 years) who underwent 1,056 BPA procedures at eight institutions in Poland.
RESULTS
RESULTS
In 156 patients who underwent follow-up assessments after a median of 5.9 (IQR: 3.0-8.0) months after final BPA, the mean pulmonary arterial pressure decreased from 45.1±10.7 to 30.2±10.2 mmHg (p<0.001) and pulmonary vascular resistance from 642±341 to 324±183 dynes (p<0.001), and the six-minute walking test (6MWT) improved from 341±129 to 423±136 m (p<0.001). Pulmonary injury related to the BPA procedure occurred in 6.4% of all sessions. Eighteen patients (7.6%) died during follow-up, including 4 (1.7%) who died within 30 days after BPA. Overall survival was 92.4% (95% confidence interval [CI]: 87.6%-94.9%) three years after the initial BPA procedure.
CONCLUSIONS
CONCLUSIONS
This multicentre registry confirmed significant improvement of haemodynamic, functional, and biochemical parameters after BPA. Complication rates were low and overall survival comparable to the results of another registry. Therefore, BPA may be an important therapeutic option in patients with CTEPH in Poland.
Identifiants
pubmed: 34219663
pii: EIJ-D-21-00230
doi: 10.4244/EIJ-D-21-00230
pmc: PMC9725062
pii:
doi:
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
1104-1111Références
Kardiol Pol. 2019 Oct 25;77(10):972-974
pubmed: 31553328
Circ Cardiovasc Interv. 2016 Oct;9(10):
pubmed: 27729418
Chest. 1988 Dec;94(6):1249-53
pubmed: 2973404
Cardiorenal Med. 2020;10(1):22-31
pubmed: 31527376
Kardiol Pol. 2015;73(1):63-8
pubmed: 25625343
Circ Cardiovasc Interv. 2012 Dec;5(6):748-55
pubmed: 23192917
Ther Adv Chronic Dis. 2021 Mar 25;12:20406223211002961
pubmed: 33854746
Circulation. 2011 Nov 1;124(18):1973-81
pubmed: 21969018
Eur Respir J. 2017 Jun 8;49(6):
pubmed: 28596435
J Heart Lung Transplant. 2016 May;35(5):591-6
pubmed: 26612053
Kardiol Pol. 2013;71(12):1331
pubmed: 24399603
Circ Cardiovasc Qual Outcomes. 2017 Nov;10(11):
pubmed: 29101270
EuroIntervention. 2014 Aug;10(4):518-25
pubmed: 25138190
Int J Cardiol. 2016 Jan 15;203:228-35
pubmed: 26519672
Eur Respir J. 2019 May 18;53(5):
pubmed: 31023842
Kardiol Pol. 2017;75(7):645-654
pubmed: 28553870
Clin Appl Thromb Hemost. 2016 Jan;22(1):92-9
pubmed: 24875780
Int J Cardiol. 2019 Mar 1;278:232-237
pubmed: 30409735
Ther Adv Respir Dis. 2019 Jan-Dec;13:1753466619891529
pubmed: 31878837
Eur Respir J. 2019 Jan 24;53(1):
pubmed: 30545969
Circ Cardiovasc Interv. 2012 Dec;5(6):756-62
pubmed: 23132237
Postepy Kardiol Interwencyjnej. 2016;12(4):355-359
pubmed: 27980550
Eur Respir J. 2015 Oct;46(4):903-75
pubmed: 26318161
Heart. 2013 Oct;99(19):1415-20
pubmed: 23846611
Circulation. 2001 Jan 2;103(1):10-3
pubmed: 11136677
Eur Respir J. 2019 May 23;53(5):
pubmed: 31123025
Ann Thorac Surg. 2012 Jul;94(1):97-103; discussion 103
pubmed: 22626752
Can J Cardiol. 2019 Apr;35(4):422-429
pubmed: 30935632
J Interv Cardiol. 2017 Jun;30(3):249-255
pubmed: 28474349
Int J Cardiol. 2015 Mar 15;183:138-42
pubmed: 25662076